Actively Recruiting
Real-World Study of ARNi Therapy Compared to Antihypertensive Monotherapy for Blood Pressure Control in UAE Hypertensive Patients
Led by Novartis Pharmaceuticals · Updated on 2026-10-21
500
Participants Needed
4
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the real-world effectiveness of angiotensin receptor-neprilysin inhibitor ARNi therapy compared to antihypertensive monotherapy in lowering blood pressure among adults with hypertension in the United Arab Emirates. The study focuses on patients diagnosed with hypertension and aims to see how these treatments impact blood pressure control in everyday clinical settings. The study includes two groups one group starts or switches to ARNi treatment sacubitrilvalsartan, and the other begins antihypertensive monotherapy with either an ACE inhibitor, an ARB, or a calcium channel blocker. Patients will be observed as they receive these therapies according to their physicians direction. Participants will have their blood pressure measured at the start and during follow-up visits, with primary measurement focused on the change in mean sitting systolic blood pressure from baseline to week 4. Additional measures include diastolic blood pressure, pulse pressure, and the proportion of patients reaching target blood pressure at weeks 4 and 12. The study will continue until August 2027, with assessments occurring at these defined timepoints to monitor treatment effects and safety.
CONDITIONS
Brief Title
A Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive Patients in the United Arab Emirates
Research Team
N
Novartis Pharmaceuticals
N
Novartis Pharmaceuticals
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here